Samsung Bioepis agrees on ‘SB5’ patent conflict with AbbVie

Samsung Bioepis(CEO/President Han-Seung Ko) agreed on the patent conflict about SB5(generic name: adalimumab, biosimilar referencing Humira), a biosimilar for the treatment of autoimmune disease(Anti-TNF-α).

Samsung Bioepis announced the company signed a license agreement with AbbVie, the original company of SB5, and agreed on the patent conflict. Under the agreement, Samsung Bioepis will be a...